In vivo blocking effects of a humanized antibody to human interleukin-6 receptor on interleukin-6 function in primates

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 1217-1221

  Shinkura, Hirofumi ^a   Imazeki, Ikuo ^a   Yamazaki, Morihiro ^a   Oda, Yasuhiro ^b   Kotoh, Masao ^b   Mihara, Masahiko ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b CSK Research Park Inc   (Japan)

Author keywords

Humanized antibody; Interleukin 6; Interleukin 6 receptor; Primates

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONKEY; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; THROMBOCYTE COUNT;

EID: 0031812603     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kishimoto T: The biology of interleukin-6. Blood 74: 1-10, 1989.
2. Hirano T, Akira S, Taga T and Kishimoto T: Biological and clinical aspects of interleukin 6. Immunol Today 11: 443-449, 1990.
3. Klein B, Wijdenes J, Zhang X-G, Jourdan M, Boiron J-M, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu Z-Y, Mannoni P, Sany J and Bataille R: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78: 1198-1204, 1991.
4. Bataille R, Barlogie B, Lu ZY, Rossi J-F, Lavabre-Bertrand T, Beck T. Wijdenes J, Brochier J and Klein B: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86: 685-691, 1995.
5. Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay J-Y, Gabarre J, Gaillard J-P, Brochier J, Raphael M, Boue F and Galanaud P: Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood 84: 2472-2479, 1994.
6. Wendung D, Racadot E and Wijdenes J: Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20: 259-262, 1993.
7. Beck JT, Hsu S-M, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S and Barlogie B: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Eng J Med 330: 602-605, 1994.
8. Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R and Klein B: High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 22: 2819-2824, 1992.
9. Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi J-F and Klein B: Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 86: 3123-3131, 1995.
10. Brakenhoff JPJ, De Hon FD and Aarden LA: Development of human IL-6 receptor antagonists. Ann NY Acad Sci 762: 129-135, 1995.
11. Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T and Kishimoto T: Cloning and expression of the human interleukin-6 (BSF-2/IFNß2) receptor. Science 241: 825-828, 1988.
12. Hibi M, Murakami M, Saito M, Hirano T, Taga T and Kishimoto T: Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63: 1149-1157, 1990.
13. Hirata Y, Taga T, Hibi M, Nakano N, Hirano T and Kishimoto T: Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies. J Immunol 143: 2900-2906, 1989.
14. Okuno Y, Takahashi T, Suzuki A, Fukumoto M, Nakamura K, Fukui H, Koishihara Y, Ohsugi Y and Imura H: Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA. Exp Hematol 20: 395-400, 1992.
15. Goto H, Shimazaki C, Tatsumi T, Yamagata N, Hirata T, Ashihara E, Oku N, Inaba T, Fujita N, Koishihara Y, Ohsugi Y and Nakagawa M: Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro. Jpn J Cancer Res 85: 958-965, 1994.
16. Suzuki H, Yasukawa K, Saito T, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T and Kishimoto T: Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 22: 1989-1993, 1992.
17. Tsunenari T, Akamatsu K, Kaiho S, Sato K, Tsuchiya M, Koishihara Y, Kishimoto T and Ohsugi Y: Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma. Anticancer Res 16: 2537-2544, 1996.
18. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T and Bendig MM: Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53: 851-856, 1993.
19. Nishimoto N, Ogata A, Shima Y, Tani Y, Ogawa H, Nakagawa M, Sugiyama H, Yoshizaki K and Kishimoto T: Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med 179: 1343-1347, 1994.
20. Asano S, Okano A, Ozawa K, Nakahata T, Ishibashi T, Koike K, Kimura H, Tanioka Y, Shibuya A, Hirano T, Kishimoto T, Takaku F and Akiyama Y: In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets. Blood 75: 1602-1605, 1990.
21. Stahl CP, Zucker-Franklin D, Evatt BL and Winton EF: Effects of human interleukin-6 on megakaryocyte development and thrombocytopoiesis in primates. Blood 78: 1467-1475, 1991.
22. Mayer P, Geissler K, Valent P, Ceska M, Bettelheim P and Liehl E: Recombinant human interleukin 6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates. Exp Hematol 19: 688-696, 1991.
23. Zeidler C, Kanz L, Hurkuck F, Rittmann KL, Wildfang I, Kadoya T, Mikayama T, Souza L and Weite K: In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates. Blood 80: 2740-2745, 1992.
24. Ryffel B, Car BD, Woerly G, Weber M, DiPadova F, Kammüller M, Klug S, Neubert R and Neubert D: Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acute-phase protein synthesis in a small primate-the marmoset. Blood 83: 2093-2102, 1994.
25. van Gameren MM, Willemse PHB, Mulder NH, Limburg PC, Groen HJM, Vellenge E and de Vries EGE: Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 84: 1434-1441, 1994.
26. D'Hondt V, Humblet Y, Guillaume T, Baatout S, Chatelain C, Berliere M, Longueville J, Feyens AM, De Greve J, Van Oosterom A, Von Graffenried B, Donnez J and Symann M: Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study. Blood 85: 2347-2353, 1995.
27. Yasukawa K, Saito T, Fukunaga T, Sekimori Y, Koishihara Y, Fukui H, Ohsugi Y, Matsuda T, Yawata H, Hirano T, Taga T and Kishimoto T: Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem 108: 673-676, 1990.
28. Pimm MV, Perkins AC, Armitage NC and Baldwin RW: The characteristics of blood-bone radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients. J Nucl Med 26: 1011-1023, 1985.
29. Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, Carrano R and LoBuglio AF: Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst 80: 937-942, 1988.
30. Brown PS, Parenteau GL, Dirbas FM, Garsia RJ, Goldman CK, Bukowski MA, Junghans RP, Queen C, Hakimi J, Benjamin WR, Clark RE and Waldmann TA: Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 88: 2663-2667, 1991.
31. Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, Pilson RS, Lin P, Weber DV, Spence C, Mondini LJ, Tsien W-H, Levin JL, Gallati VH, Korn L, Waldmann TA, Queen C and Benjamin WR: Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol 147: 1352-1359, 1991.
32. Delmonico FL, Cosimi AB, Kawai T, Cavender D, Lee W-H, Jolliffe LK and Knowles RW: Nonhuman primate responses to murine and humanized OKT4A. Transplantation 55: 722-728, 1993.
33. Stephens S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt A, Sopwith M, Athwal D, Novak C and Bodmer M: Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 85: 668-674, 1995.
34. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H and Kohler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342, 1994.
35. Heaney ML and Golde DW: Soluble cytokine receptors. Blood 87: 847-857, 1996.
36. Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, Osugi Y, Tokunaga T and Kishimoto T: Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 148: 2175-2180, 1992.
37. Gaillard J-P, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga T, Kishimoto T and Klein B: Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 23: 820-824, 1993.
38. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, Kishimoto T and Suda T: Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Pros Natl Acad Sci USA 90: 11924-11928, 1993.